advisory clinical Team



Dr. Kelly McKee, Jr., MD, MPH

Chief Scientific Officer Consultant

Dr. McKee is currently Senior Scientific and Medical Advisor for Pharm-Olam. Previously, Dr. McKee served Pharm-Olam’s Chief Medical Officer, and as Vice President, Vaccines and Public Health, in the Infectious Diseases and Vaccines Center of Excellence at IQVIA (previously QuintilesIMS).  He brings over 30 years of experience in research and development from the bench to the bedside, with specific expertise in vaccines, emerging diseases, biodefense, respiratory viral infections, and sexually transmitted infections. His progressive clinical research experience began in 1981 at Fort Detrick, Frederick, Md., United States, where he served as a research virologist, immunologist, and Head of the Dept of Clinical Investigation and Medical Division at the US Army Medical Research Institute of Infectious Diseases (USAMRIID).

Dr. Arshi Kizilbash, M.D.

Dr. Kizilbash is the CEO and Chief Medical Officer of Delta Health, a multi-functional global healthcare company. He has specialized in Internal Medicine, including post-graduate medical training from the Harvard Medical School and has also been mentored and trained by a Nobel Prize winner in Medicine. Dr. Kizilbash has extensive experience in the clinical development of new drugs, biologics and medical devices spanning over 20 years. He has worked directly with the United States FDA, Health Canada and other international regulatory agencies and has been credited with the successful development of a number of prominent prescription drugs that are being used to treat patients in the United States, Canada and a number of other countries around the world.

Dr. Onesmo Mpanju, PHD
ChIEF regulatory consultant

Dr. Onesmo Mpanju, PhD has over 28 years of experience in biopharmaceutical R&D, including 18 years as a regulatory scientist. Previously, Dr. Mpanju was a Reviewer at the U.S. FDA, Center for Biologics Evaluation & Research. His consulting experience includes non-commercial entities such as the U.S. National Institutes of Health, US Army Medical Materiel Development Activity (USAMMDA), the Bill & Melinda Gates Foundation, and others. Dr. Mpanju holds a Ph.D. in Experimental Medicine (Infectious Diseases) from the University of British Columbia, Vancouver, Canada.

Dr. John Fahy

Scientific and Clinical Advisor

Dr. John Fahy, MD, MSc is a Professor of Medicine in the Division of Pulmonary and Critical Care Medicine and the Department of Medicine at the University of California San Francisco and is a director of UCSF’s severe asthma clinic. He also cares for critically ill patients in the intensive care units and directs the UCSF Airway Clinical Research Center. His research receives funding from the National Institutes of Health and various foundations, as well as contracts from biotechnology and pharmaceutical companies in disease mechanisms of asthma, cystic fibrosis and other airway diseases.